Alteogen Inc. (CEO Park Soon-jae) announced that it has been selected as a 'Youth-Attractive Company' in the 'Daejeon Settlement-Type Youth Employment Comprehensive Project' operated by Daejeon Metropolitan City (Mayor Lee Jang-woo) and the InnoPolis Venture Association (Chairman Cho Won-hee).

Since 2024, Daejeon City has been selecting and supporting companies that are attractive to youth, with excellent wage, income, job stability, and work-life balance. The goal is to enhance corporate competitiveness by improving local youth's perception of regional companies and motivating employment.

Applications were received from outstanding companies based in Daejeon City, and after a first quantitative evaluation on △corporate growth potential △work-life balance △wages △wage innovation capability, the Youth-Attractive Evaluation Team conducted a second on-site evaluation through interviews with HR managers and young employees, selecting Alteogen.

Founded in 2008, Alteogen is a technology-leading bio-venture company engaged in the research and development of biopharmaceuticals, next-generation biobetters, and biosimilars. It is developing next-generation biobetters with improved efficacy over existing biopharmaceuticals and biosimilar drugs with equivalent efficacy using its independently developed and owned platform technology.

In particular, NexP Fusion is a fundamental technology for developing next-generation biopharmaceuticals. The NexP sustained-release technology is being applied to develop next-generation sustained-release human growth hormones and sustained-release hemophilia treatments. The next-generation sustained-release human growth hormone is currently in Phase 2 clinical trials. Research and development of biopharmaceuticals and Biobetter treatments for non-alcoholic steatohepatitis (NASH), acromegaly, macular degeneration, and osteoporosis are also underway.

NexMab ADC is based on the NexMab ADC technology, which boasts superior stability, efficacy, and cost-effectiveness. It is being used to develop ADC anticancer drugs targeting breast and gastric cancer, as well as ovarian and lung cancer. The ADC anticancer drug targeting breast and gastric cancer has successfully completed domestic Phase 1 clinical trials, and preparations for global Phase 2 clinical trials are underway, with continued research and development of new target antibodies.

Hybrozyme is a technology that converts intravenous formulations into subcutaneous formulations. This core technology is being applied to develop products that can convert antibody drugs requiring large doses into intravenous formulations, based on human-derived hyaluronidase.

In addition, Alteogen possesses proprietary biosimilar technology. It is jointly developing blockbuster-level cancer antibody biosimilars with pharmaceutical companies in China, Brazil, and Japan. From cell lines to processes and analytical methods, all are developed in-house, generating annual technology transfer milestone revenues of KRW 1 to 4 billion through step-by-step technology transfers.

Park Soon-jae, CEO of Alteogen, stated, “Alteogen will receive support for operating a dedicated Youth-Attractive Manager, awareness improvement programs (such as culture books, brochures, IR material production support), and company-youth matching days,” and added, “We will strengthen our corporate competitiveness by recruiting excellent local talent and enhancing our proprietary technology.”

Popular News